A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.

In a recent phase III trial, however, extended radical transthoracic esophagectomy showed a trend to a better survival when compared with a less radical transhiatal esophagectomy, indicating that an adequate locoregional treatment may have a beneficial effect on survival. 3 However, in both groups a R0 resection rate of only 72% was noted.

also in 53,322 other papers